TNYA Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 111763 min ago

@ $5.35

Išleistas: 14 vas. 2024 @ 16:30

Grąža: -12.52%

Ankstesnis signalas: vas. 12 - 18:24

Ankstesnis signalas: Pirkimas

Grąža: -6.14 %

Live Chart Being Loaded With Signals

Commentary (1 geg. 2024 @ 23:00):

Stats
Šios dienos apimtis	152 978
Vidutinė apimtis	526 504
Rinkos kapitalizacija	367.46M
EPS	$-0.390 ( 2024-03-20 )
Kita pelno data	( $-0.430 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.79
ATR14	$0.0120 (0.26%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-05	Hoey Timothy	Sell	3 300	Common Stock
2024-02-23	Hoey Timothy	Buy	12 500	Common Stock
2024-02-23	Hoey Timothy	Buy	75 000	Stock Option (Right to buy)
2024-02-23	Tingley Whittemore	Buy	215 000	Stock Option (Right to buy)
2024-02-23	Tingley Whittemore	Buy	35 000	Common Stock

INSIDER POWER
99.35
Last 96 transactions
Buy: 62 840 535 \| Sell: 9 767 330

Tūris Koreliacija

Ilgas: 0.35 (neutral)

Trumpas: -0.74 (moderate negative)

Signal:(31.141) Neutral

Tenaya Therapeutics, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
MDRR	0.829
RESN	0.81

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Tenaya Therapeutics, Inc. Koreliacija - Valiuta/Žaliavos

0.61
( weak )

0.51
( weak )

0.00
( neutral )

0.77
( moderate )

-0.88
( strong negative )

Tenaya Therapeutics, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-8.69M (0.00 %)
EPS:	$-1.680

FY	2023
Pajamos:	$0
Bruto pelnas:	$-8.69M (0.00 %)
EPS:	$-1.680

FY	2022
Pajamos:	$0
Bruto pelnas:	$-8.71M (0.00 %)
EPS:	$-2.76

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.00269

Financial Reports:

No articles found.

Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.